Abstract:Gemechu Churiso, 1 Gose Husen, 2 Denebo Bulbula, 2 Lulu Abebe 3 1 Department of Medical Laboratory Sciences, Dilla University, Dilla, Ethiopia; 2 Department of Orthopedic Surgery, Dilla University, Dilla, Ethiopia; 3 Department of Psychiatry, Dilla University, Dilla, Ethiopia Correspondence: Gemechu Churiso, Email Antigen-presenting cells recognize respiratory syncytial virus antigens, and produce cytokines and chemokines that act on immune cells. Dendritic cells play the main role in inflammatory cytokine responses. Similarly, alveolar macrophages produce IFN-β, IFN-α, TNF-α, IL-6, CXCL10, and CCL3, while alternatively activated macrophages differentiate at the late phase, and require IL-13 or IL-4 cytokines. Furthermore, activated NKT cells secrete IL-13 and IL-4 that cause lung epithelial, endothelial and fibroblasts to secrete eotaxin that enhances the recruitment of eosinophil to the lung. CD8 + and CD4 + T cells infection by the virus decreases the IFN-γ and IL-2 production. Despite this, both are involved in terminating virus replication. CD8 + T cells produce a larger amount of IFN-γ than CD4 + T cells, and CD8 + T cells activated under type 2 conditions produce IL-4, down regulating CD8 expression, granzyme and IFN-γ production. Antiviral inhibitors inhibit biological functions of viral proteins. Some of them directly target the virus replication machinery and are effective at later stages of infection; while others inhibit F protein dependent fusion and syncytium formation. TMC353121 reduces inflammatory cytokines, TNF-α, IL-6, and IL-1β and chemokines, KC, IP-10, MCP and MIP1-α. EDP-938 inhibits viral nucleoprotein (N), while GRP-156784 blocks the activity of respiratory syncytial virus ribonucleic acid (RNA) polymerase. PC786 inhibits non-structural protein 1 (NS-1) gene, RANTES transcripts, virus-induced CCL5, IL-6, and mucin increase. In general, it is an immune reaction that is blamed for the disease severity and pathogenesis in respiratory syncytial virus infection. Anti-viral inhibitors not only inhibit viral entry and replication, but also may reduce inflammatory cytokines and chemokines. Many respiratory syncytial virus inhibitors are proposed; however, only palivizumab and ribavirin are approved for prophylaxis and treatment, respectively. Hence, this review is focused on immunity cell responses to respiratory syncytial virus and the role of antiviral inhibitors. Keywords: immune cells, respiratory syncytial virus, antiviral inhibitors Respiratory syncytial virus (RSV) is an enveloped negative sense RNA virus that has trans membrane surface proteins like F, G and SH, and non-glycosylated virion matrix protein (M), proteins associated with RNA to form viral nucleocapsid (P, N, L and M2 open reading frame 1), and other proteins that are non-structural viral products (NS1 and NS2). 1,2 It causes lower respiratory tract infection affecting mostly elder people and children. 3,4 The RSV virus has 2 main subtypes; subtype A and B. 5 Luminal columnar cells, especially ciliated cells, can be affected by RSV, and the virus can be shed solely from the apical surface of ciliated cells and spread to neighbouring cells by the cilial beats. 6 RSV G protein interaction with C-X-C Motif Chemokine Receptor 1 (CXCR1) on the cell surface of human amniotic epithelial cells (HAECs) is very important to the pathogenesis of the virus. It contributed to around 50% of RSV infectivity in these cells. CXCR1 is predominantly detected on the ciliated cells, and the percentage of these receptors is varied from person to person. 7 Infected people show symptoms like cough, sneezing, runny nose, fever, decrease in appetite, and wheezing within 4 to 6 days of infection. 8 The virus can cause severe infection that includes bronchitis, pneumonia, inflammation of the small airways in the lung, and is common in children younger than one year of age. Older adults and infants earlier than six months of age may need hospitalization and additional oxygen or intubation. 9 Innate and adaptive immunities are induced during RSV infection. Innate immune cells and other virally infected cells secret inflammatory cytokines, which attract and activate immune cells that induce acute inflammation that helps virus clearance. 3 Cellular immunities are very important to clear the RSV infection; 10 unlike virus-neutralizing antibodies that are induced and suboptimal during initial infection and wanes over time. Despite this, re-infection with the virus is common. Even though cellular immunities are very important for the clearance of the virus, they can cause serious lower respiratory tract bronchitis immune pathogenesis. 11</su -Abstract Truncated-

Autophagy and TGF-β regulates innate immune response in human respiratory syncytial virus infected macrophages

Respiratory syncytial virus-induced high mobility group box 1 secretion modulates innate immune response to promote inflammation

Innate antiviral host defense attenuates TGF-β function through IRF3-mediated suppression of Smad signaling.

Regulation Of Viral Infection-Induced Airway Remodeling Cytokine Production By The Tlr3-Egfr Signaling Pathway In Human Bronchial Epithelial Cells

Rhinovirus-induced IFNβ expression is NFκB-dependent and regulated by the macrophage microenvironment

Autophagy-inducing protein beclin-1 in dendritic cells regulates CD4 T cell responses and disease severity during respiratory syncytial virus infection

Human Respiratory Syncytial Virus NS2 Protein Induces Autophagy by Modulating Beclin1 Protein Stabilization and ISGylation

Combined blockade of IFN-Type I and TNF alpha receptors provides protection against respiratory syncytial virus (RSV)-induced disease and bronchoconstriction

Interaction of Ectodomain of Respiratory Syncytial Virus G Protein with TLR2/TLR6 Heterodimer: An <i>In vitro</i> and <i>In silico</i> Approach to Decipher the Role of RSV G Protein in Pro-inflammatory Response against the Virus

Interaction of Ectodomain of Respiratory Syncytial Virus G Protein with TLR2/ TLR6 Heterodimer: An In vitro and In silico Approach to Decipher the Role of RSV G Protein in Pro-inflammatory Response against the Virus

Differential Role of Anti-Viral Sensing Pathway for the Production of Type I Interferon β in Dendritic Cells and Macrophages Against Respiratory Syncytial Virus A2 Strain Infection

Inhibition of NF-κB/IL-33/ST2 Axis Ameliorates Acute Bronchiolitis Induced by Respiratory Syncytial Virus

Respiratory Syncytial Virus Replication is Promoted by Autophagy-Mediated Inhibition of Apoptosis

Respiratory syncytial virus induces RelA release from cytoplasmic 100-kDa NF-kappa B2 complexes via a novel retinoic acid-inducible gene-I{middle dot}NF- kappa B-inducing kinase signaling pathway

Respiratory syncytial virus infection induces the release of transglutaminase 2 from human airway epithelial cells

BRD4 Couples NF-κB/RelA with Airway Inflammation and the IRF-RIG-I Amplification Loop in Respiratory Syncytial Virus Infection

T cell responses are elicited against Respiratory Syncytial Virus in the absence of signalling through TLRs, RLRs and IL-1R/IL-18R

The respiratory syncytial virus fusion protein formulated with a polymer-based adjuvant induces multiple signaling pathways in macrophages

Respiratory syncytial virus nonstructural protein 1 breaks immune tolerance in mice by downregulating Tregs through TSLP-OX40/OX40L-mTOR axis

Alveolar Macrophages Can Control Respiratory Syncytial Virus Infection in the Absence of Type I Interferons

Immunity Cell Responses to RSV and the Role of Antiviral Inhibitors: A Systematic Review